Biohaven is still studying its glutamate modulator in three other indications, but its biggest near-term milestone will be approval of the oral CGRP inhibitor rimegepant for acute migraine.

Aimovig, Emgality and Ajovy have been on the market for more than a year, but are still far from blockbusters even though millions of patients are eligible for treatment – and at least one new competitor is coming.

Danish neuroscience company plans to acquire Abide Therapeutics for $250m upfront and up to $150m in milestones to access serine hydrolase drug discovery platform.